Major pharmaceutical companies, including Boehringer Ingelheim and Eli Lilly, have significantly cut investment plans in Germany due to new healthcare reforms, raising industry and political concerns.
Major pharmaceutical companies, including Boehringer Ingelheim and Eli Lilly, have significantly cut investment plans in Germany due to new healthcare reforms, raising industry and political concerns.
Germany is under intensified international scrutiny from Russia at the UN and faces growing normalization of the far-right AfD within its domestic politics, threatening its global reputation and democratic values in 2026.
The full closure of the Brennerautobahn on May 30 will heavily impact Oberfranken logistics firms and prompt local protests demanding traffic restrictions and noise barriers.